Inquiry Basket
Loading ......
Filter By Product Search for
CUL9
CUL9 Full Name
cullin 9
CUL9 Introduction
CUL9 (cullin 9), also known as PARC (p53-associated Parkin-like cytoplasmic protein), is a vertebrate-specific member of the Cullin-RING E3 ubiquitin ligase family and represents one of the least characterized cullins despite increasing interest in its biological significance. Unlike classical cullin proteins, CUL9 possesses several unusual structural features, including a large cytoplasmic localization pattern, the ability to associate with p53, and the presence of both cullin-RING and RBR (RING-between-RING) characteristics that distinguish it from other CRL family members. Recent structural studies have revealed that CUL9 forms an approximately 1.8 MDa hexameric CUL9-RBX1 complex and requires UBE2F-mediated neddylation for activation, establishing a unique hybrid ubiquitination mechanism that combines canonical Cullin-RING activity with RBR-mediated functions. These discoveries have addressed long-standing questions regarding the catalytic organization of CUL9 and have positioned the protein as a distinctive regulator within the ubiquitin-proteasome system, making it increasingly relevant to researchers seeking novel targets involved in protein homeostasis and cellular stress responses.
From a functional perspective, CUL9 serves as a scaffold protein for assembling E3 ubiquitin ligase complexes and participates in multiple signaling pathways associated with cell cycle control, protein degradation, transcriptional regulation, and cellular differentiation. Experimental evidence indicates that CUL9 interacts with components of the anaphase-promoting complex/cyclosome (APC/C), suggesting crosstalk between ubiquitin-mediated proteolysis and major cell cycle regulatory networks. Proteomic studies using induced pluripotent stem cell models have shown that depletion of CUL9 disrupts neural rosette formation, implicating the protein in early neuronal development and stem cell biology. Loss of CUL9 alters pathways related to metabolism, ubiquitin-dependent degradation, and gene expression without causing significant changes in ATP production or oxygen consumption, highlighting its selective regulatory role rather than a direct effect on cellular energy metabolism. The emerging evidence suggests that CUL9 functions as an important coordinator of protein quality control and developmental signaling, areas that remain under active investigation.
Increasing clinical and translational studies have linked abnormal CUL9 expression to human malignancies, particularly colorectal cancer. Elevated CUL9 expression has been identified as a significant prognostic biomarker in high-risk stage II and stage III colon cancer, where increased expression correlates with unfavorable survival outcomes and may predict responsiveness to adjuvant chemotherapy. Comprehensive genomic and bioinformatic analyses have further demonstrated that CUL9 is frequently upregulated in colorectal tumors and is closely associated with alterations in the tumor immune microenvironment, mutation patterns, and cancer progression pathways. Functional studies in colorectal cancer cell lines support a growth-promoting role for CUL9, strengthening the rationale for considering CUL9 as a potential therapeutic target. Beyond cancer, its involvement in p53 regulation, ubiquitin signaling, and neuronal differentiation suggests broader implications in developmental disorders and diseases characterized by dysregulated proteostasis. As understanding of this atypical E3 ligase continues to expand, CUL9 is increasingly recognized as a promising biomarker and an emerging target for precision medicine strategies aimed at modulating ubiquitin-dependent pathways.
Alternate Names for CUL9
CUL9; cullin 9; PARC; H7AP1; cullin-9; CUL-9; UbcH7-associated protein 1; parkin-like cytoplasmic p53 binding protein; p53-associated parkin-like cytoplasmic protein;
Loading ......
